{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:33:54Z","timestamp":1649118834535},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:00:00Z","timestamp":1581984000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:00:00Z","timestamp":1581984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s00120-020-01149-1","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T13:03:01Z","timestamp":1582030981000},"page":"347-358","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Neue operative Techniken zur Therapie des benignen Prostatasyndroms"],"prefix":"10.1007","volume":"59","author":[{"given":"D. S.","family":"Sch\u00f6b","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. C.","family":"Reichelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. J.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Abt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Miernik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Gratzke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,18]]},"reference":[{"issue":"Suppl 3","key":"1149_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000052345","volume":"36","author":"RR Berges","year":"1999","unstructured":"Berges\u00a0RR, Pientka\u00a0L (1999) Management of the BPH syndrome in Germany: who is treated and how? Eur Urol 36(Suppl 3):21\u201327","journal-title":"Eur Urol"},{"key":"1149_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.urology.2016.06.021","volume":"95","author":"S Rohrmann","year":"2016","unstructured":"Rohrmann\u00a0S, Katzke\u00a0V, Kaaks\u00a0R (2016) Prevalence and progression of lower urinary tract symptoms in an aging population. Urology 95:158\u2013163","journal-title":"Urology"},{"issue":"4","key":"1149_CR3","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.eururo.2007.08.042","volume":"53","author":"JL Bosch","year":"2008","unstructured":"Bosch\u00a0JL, Bangma\u00a0CH, Groeneveld\u00a0FP, Bohnen\u00a0AM (2008) The long-term relationship between a\u00a0real change in prostate volume and a\u00a0significant change in lower urinary tract symptom severity in population-based men: the Krimpen study. Eur Urol 53(4):819\u2013825 (discussion 25\u20137)","journal-title":"Eur Urol"},{"issue":"5","key":"1149_CR4","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.juro.2010.01.026","volume":"183","author":"JK Parsons","year":"2010","unstructured":"Parsons\u00a0JK, Wilt\u00a0TJ, Wang\u00a0PY, Barrett-Connor\u00a0E, Bauer\u00a0DC, Marshall\u00a0LM (2010) Progression of lower urinary tract symptoms in older men: a\u00a0community based study. J\u00a0Urol 183(5):1915\u20131920","journal-title":"J Urol"},{"issue":"1","key":"1149_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1464-410X.2005.05240.x","volume":"95","author":"SJ Hong","year":"2005","unstructured":"Hong\u00a0SJ, Rayford\u00a0W, Valiquette\u00a0L, Emberton\u00a0M (2005) The importance of patient perception in the clinical assessment of benign prostatic hyperplasia and its management. BJU Int 95(1):15\u201319","journal-title":"BJU Int"},{"issue":"6","key":"1149_CR6","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.eururo.2014.12.038","volume":"67","author":"C Gratzke","year":"2015","unstructured":"Gratzke\u00a0C, Bachmann\u00a0A, Descazeaud\u00a0A, Drake\u00a0MJ, Madersbacher\u00a0S, Mamoulakis\u00a0C et al (2015) EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 67(6):1099\u20131109","journal-title":"Eur Urol"},{"key":"1149_CR7","unstructured":"Inc AUAEaR. American Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH)Revised, 2010"},{"issue":"5","key":"1149_CR8","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/S0090-4295(94)80208-4","volume":"44","author":"GL Lu-Yao","year":"1994","unstructured":"Lu-Yao\u00a0GL, Barry\u00a0MJ, Chang\u00a0C\u2011H, Wasson\u00a0JH, Wennberg\u00a0JE, Team\u00a0PPOR (1994) Transurethral resection of the prostateamong medicare beneficiaries in the United States: time trends and outcomes. Urology 44(5):692\u2013698","journal-title":"Urology"},{"issue":"3","key":"1149_CR9","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s00120-019-0876-7","volume":"58","author":"G Magistro","year":"2019","unstructured":"Magistro\u00a0G, Stief\u00a0C, Gratzke\u00a0C (2019) Neue minimal-invasive Therapie des benignen Prostatasyndroms. Urologe 58(3):254\u2013262","journal-title":"Urologe"},{"issue":"2","key":"1149_CR10","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/bju.12982","volume":"116","author":"F Porpiglia","year":"2015","unstructured":"Porpiglia\u00a0F, Fiori\u00a0C, Bertolo\u00a0R, Garrou\u00a0D, Cattaneo\u00a0G, Amparore\u00a0D (2015) Temporary implantable nitinol device (TIND): a\u00a0novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow-up. BJU Int 116(2):278\u2013287","journal-title":"BJU Int"},{"issue":"1","key":"1149_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/bju.14141","volume":"122","author":"F Porpiglia","year":"2018","unstructured":"Porpiglia\u00a0F, Fiori\u00a0C, Bertolo\u00a0R, Giordano\u00a0A, Checcucci\u00a0E, Garrou\u00a0D et al (2018) 3\u2011Year follow-up of temporary implantable nitinol device implantation for the treatment of benign prostatic obstruction. BJU Int 122(1):106\u2013112","journal-title":"BJU Int"},{"issue":"6","key":"1149_CR12","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/bju.14608","volume":"123","author":"F Porpiglia","year":"2019","unstructured":"Porpiglia\u00a0F, Fiori\u00a0C, Amparore\u00a0D, Kadner\u00a0G, Manit\u00a0A, Valerio\u00a0M et al (2019) Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a\u00a0prospective, multicentre study at 1 year of follow-up. BJU Int 123(6):1061\u20131069","journal-title":"BJU Int"},{"issue":"8","key":"1149_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11934-019-0912-6","volume":"20","author":"D Amparore","year":"2019","unstructured":"Amparore\u00a0D, De Cillis\u00a0S, Volpi\u00a0G, Checcucci\u00a0E, Manfredi\u00a0M, Morra\u00a0I et al (2019) First- and second-generation temporary Implantable nitinol devices as minimally invasive treatments for BPH-related LUTS: systematic review of the literature. Curr Urol Rep 20(8):47","journal-title":"Curr Urol Rep"},{"key":"1149_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-018-0118-x","author":"D Rukstalis","year":"2018","unstructured":"Rukstalis\u00a0D, Grier\u00a0D, Stroup\u00a0S, Tutrone\u00a0R, deSouza\u00a0E, Freedman\u00a0S et\u00a0al (2018) Prostatic Urethral Lift (PUL) for obstructive median lobes: 12 month results of the MedLift Study. Prostate Cancer Prostatic Dis. https:\/\/doi.org\/10.1038\/s41391-018-0118-x","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"7","key":"1149_CR15","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s00345-018-2494-1","volume":"37","author":"KD Sievert","year":"2019","unstructured":"Sievert\u00a0KD, Schonthaler\u00a0M, Berges\u00a0R, Toomey\u00a0P, Drager\u00a0D, Herlemann\u00a0A et\u00a0al (2019) Minimally invasive prostatic urethral lift (PUL) efficacious in TURP candidates: a\u00a0multicenter German evaluation after 2 years. World J Urol 37(7):1353\u20131360","journal-title":"World J Urol"},{"issue":"8","key":"1149_CR16","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1089\/end.2017.0224","volume":"31","author":"S McAdams","year":"2017","unstructured":"McAdams\u00a0S, Funk\u00a0JT, Navetta\u00a0AF, El Tayeb\u00a0MM, Humphreys\u00a0MR (2017) Holmium laser enucleation of the prostate after prostatic urethral lift surgery: feasibility and technical considerations from a\u00a0multi-institutional case series. J\u00a0Endourol 31(8):774\u2013779","journal-title":"J Endourol"},{"key":"1149_CR17","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.urology.2016.11.029","volume":"104","author":"A Keehn","year":"2017","unstructured":"Keehn\u00a0A, Fram\u00a0E, Garg\u00a0M, Maria\u00a0P (2017) Urolift in place of fiducial markers for patients with benign prostatic hyperplasia undergoing external beam radiation therapy. Urology 104:230\u2013234","journal-title":"Urology"},{"issue":"6","key":"1149_CR18","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/j.juro.2013.05.116","volume":"190","author":"CG Roehrborn","year":"2013","unstructured":"Roehrborn\u00a0CG, Gange\u00a0SN, Shore\u00a0ND, Giddens\u00a0JL, Bolton\u00a0DM, Cowan\u00a0BE et\u00a0al (2013) The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. J\u00a0Urol 190(6):2161\u20132167","journal-title":"J Urol"},{"issue":"7","key":"1149_CR19","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1089\/end.2019.0167","volume":"33","author":"G Eure","year":"2019","unstructured":"Eure\u00a0G, Gange\u00a0S, Walter\u00a0P, Khan\u00a0A, Chabert\u00a0C, Mueller\u00a0T et al (2019) Real-world evidence of prostatic urethral lift confirms pivotal clinical study results: 2\u2011year outcomes of a\u00a0retrospective multicenter study. J\u00a0Endourol 33(7):576\u2013584","journal-title":"J Endourol"},{"issue":"4","key":"1149_CR20","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.eururo.2015.04.024","volume":"68","author":"J Sonksen","year":"2015","unstructured":"Sonksen\u00a0J, Barber\u00a0NJ, Speakman\u00a0MJ, Berges\u00a0R, Wetterauer\u00a0U, Greene\u00a0D et al (2015) Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. Eur Urol 68(4):643\u2013652","journal-title":"Eur Urol"},{"issue":"5","key":"1149_CR21","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/bju.13714","volume":"119","author":"C Gratzke","year":"2017","unstructured":"Gratzke\u00a0C, Barber\u00a0N, Speakman\u00a0MJ, Berges\u00a0R, Wetterauer\u00a0U, Greene\u00a0D et al (2017) Prostatic urethral lift vs transurethral resection of the prostate: 2\u2011year results of the BPH6 prospective, multicentre, randomized study. BJU Int 119(5):767\u2013775","journal-title":"BJU Int"},{"key":"1149_CR22","first-page":"207","volume":"8","author":"CM Dixon","year":"2016","unstructured":"Dixon\u00a0CM, Cedano\u00a0ER, Pacik\u00a0D, Vit\u00a0V, Varga\u00a0G, Wagrell\u00a0L et al (2016) Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia. Res Rep Urol 8:207\u2013216","journal-title":"Res Rep Urol"},{"key":"1149_CR23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.urology.2018.12.041","volume":"126","author":"KT McVary","year":"2019","unstructured":"McVary\u00a0KT, Rogers\u00a0T, Roehrborn\u00a0CG (2019) Rezum water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4\u2011year results from randomized controlled study. Urology 126:171\u2013179","journal-title":"Urology"},{"issue":"3","key":"1149_CR24","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41391-017-0022-9","volume":"21","author":"D Mollengarden","year":"2018","unstructured":"Mollengarden\u00a0D, Goldberg\u00a0K, Wong\u00a0D, Roehrborn\u00a0C (2018) Convective radiofrequency water vapor thermal therapy for benign prostatic hyperplasia: a\u00a0single office experience. Prostate Cancer Prostatic Dis 21(3):379\u2013385","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1149_CR25","first-page":"159","volume":"9","author":"MF Darson","year":"2017","unstructured":"Darson\u00a0MF, Alexander\u00a0EE, Schiffman\u00a0ZJ, Lewitton\u00a0M, Light\u00a0RA, Sutton\u00a0MA et\u00a0al (2017) Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rezum system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Res Rep Urol 9:159\u2013168","journal-title":"Res Rep Urol"},{"issue":"12","key":"1149_CR26","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.jsxm.2018.10.006","volume":"15","author":"KT McVary","year":"2018","unstructured":"McVary\u00a0KT, Rogers\u00a0T, Mahon\u00a0J, Gupta\u00a0NK (2018) Is sexual function better preserved after water vapor thermal therapy or medical therapy for lower urinary tract symptoms due to benign prostatic Hyperplasia? J\u00a0Sex Med 15(12):1728\u20131738","journal-title":"J Sex Med"},{"issue":"3","key":"1149_CR27","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s00120-019-0876-7","volume":"58","author":"G Magistro","year":"2019","unstructured":"Magistro\u00a0G, Stief\u00a0CG, Gratzke\u00a0C (2019) Neue minimal-invasive Therapie des benignen Prostatasyndroms. Urologe 58(3):254\u2013262","journal-title":"Urologe"},{"issue":"5","key":"1149_CR28","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.juro.2017.12.065","volume":"199","author":"P Gilling","year":"2018","unstructured":"Gilling\u00a0P, Barber\u00a0N, Bidair\u00a0M, Anderson\u00a0P, Sutton\u00a0M, Aho\u00a0T et al (2018) WATER: a double-blind, randomized, controlled trial of aquablation((R)) vs transurethral resection of the prostate in benign prostatic hyperplasia. J\u00a0Urol 199(5):1252\u20131261","journal-title":"J Urol"},{"key":"1149_CR29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.urology.2018.12.002","volume":"125","author":"PJ Gilling","year":"2019","unstructured":"Gilling\u00a0PJ, Barber\u00a0N, Bidair\u00a0M, Anderson\u00a0P, Sutton\u00a0M, Aho\u00a0T et al (2019) Randomized controlled trial of aquablation versus transurethral resection of the prostate in benign prostatic hyperplasia: one-year outcomes. Urology 125:169\u2013173","journal-title":"Urology"},{"key":"1149_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.urology.2019.04.029","volume":"129","author":"Naeem Bhojani","year":"2019","unstructured":"Bhojani N, Bidair M, Zorn KC, Trainer A, Arther A, Kramolowsky E et\u00a0al (2019) Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150 cc): 1-Year Results. Urology 129:1\u20137","journal-title":"Urology"},{"issue":"2","key":"1149_CR31","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/bju.14703","volume":"124","author":"M Desai","year":"2019","unstructured":"Desai\u00a0M, Bidair\u00a0M, Zorn\u00a0KC, Trainer\u00a0A, Arther\u00a0A, Kramolowsky\u00a0E et al (2019) Aquablation for benign prostatic hyperplasia in large prostates (80\u2013150\u202fmL): 6\u2011month results from the WATER II trial. BJU Int 124(2):321\u2013328","journal-title":"BJU Int"},{"issue":"4","key":"1149_CR32","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jvir.2012.12.019","volume":"24","author":"FC Carnevale","year":"2013","unstructured":"Carnevale\u00a0FC, da Motta-Leal-Filho\u00a0JM, Antunes\u00a0AA, Baroni\u00a0RH, Marcelino\u00a0ASZ, Cerri\u00a0LMO et al (2013) Quality of life and clinical symptom improvement support prostatic artery embolization for patients with acute urinary retention caused by benign prostatic Hyperplasia. J\u00a0Vasc Interv Radiol 24(4):535\u2013542","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"1149_CR33","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00270-015-1083-6","volume":"38","author":"A Laborda","year":"2015","unstructured":"Laborda\u00a0A, De Assis\u00a0AM, Ioakeim\u00a0I, S\u00e1nchez-Ballest\u00edn\u00a0M, Carnevale\u00a0FC, De Gregorio\u00a0MA (2015) Radiodermitis after prostatic artery embolization: case report and review of the literature. Cardiovasc Intervent Radiol 38(3):755\u2013759","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"1149_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/bju.13147","volume":"117","author":"M Wang","year":"2016","unstructured":"Wang\u00a0M, Guo\u00a0L, Duan\u00a0F, Yuan\u00a0K, Zhang\u00a0G, Li\u00a0K et al (2016) Prostatic arterial embolization for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia: a\u00a0comparative study of medium- and large-volume prostates. BJU Int 117(1):155\u2013164","journal-title":"BJU Int"},{"issue":"9","key":"1149_CR35","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1007\/s00330-012-2714-9","volume":"23","author":"JM Pisco","year":"2013","unstructured":"Pisco\u00a0JM, Rio Tinto\u00a0H, Campos Pinheiro\u00a0L, Bilhim\u00a0T, Duarte\u00a0M, Fernandes\u00a0L et al (2013) Embolisation of prostatic arteries as treatment of moderate to severe lower urinary symptoms (LUTS) secondary to benign hyperplasia: results of short- and mid-term follow-up. Eur Radiol 23(9):2561\u20132572","journal-title":"Eur Radiol"},{"issue":"1","key":"1149_CR36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00270-015-1202-4","volume":"39","author":"FC Carnevale","year":"2016","unstructured":"Carnevale\u00a0FC, Iscaife\u00a0A, Yoshinaga\u00a0EM, Moreira\u00a0AM, Antunes\u00a0AA, Srougi\u00a0M (2016) Transurethral Resection of the Prostate (TURP) Versus Original and PErFecTED Prostate Artery Embolization (PAE) Due to Benign Prostatic Hyperplasia (BPH): Preliminary Results of a\u00a0Single Center, Prospective, Urodynamic-Controlled Analysis. Cardiovasc Intervent Radiol 39(1):44\u201352","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"1149_CR37","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1148\/radiol.13122803","volume":"270","author":"Y-A Gao","year":"2014","unstructured":"Gao\u00a0Y\u2011A, Huang\u00a0Y, Zhang\u00a0R, Yang\u00a0Y\u2011D, Zhang\u00a0Q, Hou\u00a0M et al (2014) Benign prostatic hyperplasia: prostatic arterial embolization versus transurethral resection of the prostate\u2014a prospective, randomized, and controlled clinical trial. Radiology 270(3):920\u2013928","journal-title":"Radiology"},{"key":"1149_CR38","doi-asserted-by":"publisher","first-page":"k2338","DOI":"10.1136\/bmj.k2338","volume":"361","author":"D Abt","year":"2018","unstructured":"Abt\u00a0D, Hechelhammer\u00a0L, M\u00fcllhaupt\u00a0G, Markart\u00a0S, G\u00fcsewell\u00a0S, Kessler\u00a0TM et al (2018) Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. BMJ 361:k2338","journal-title":"BMJ"},{"issue":"2","key":"1149_CR39","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/bju.14249","volume":"122","author":"AF Ray","year":"2018","unstructured":"Ray\u00a0AF, Powell\u00a0J, Speakman\u00a0MJ, Longford\u00a0NT, DasGupta\u00a0R, Bryant\u00a0T et al (2018) Efficacy and safety of prostate artery embolization for benign prostatic hyperplasia: an observational study and propensity-matched comparison with transurethral resection of the prostate (the UK-ROPE study). BJU Int 122(2):270\u2013282","journal-title":"BJU Int"},{"issue":"2","key":"1149_CR40","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.urology.2015.04.037","volume":"86","author":"GI Russo","year":"2015","unstructured":"Russo\u00a0GI, Kurbatov\u00a0D, Sansalone\u00a0S, Lepetukhin\u00a0A, Dubsky\u00a0S, Sitkin\u00a0I et al (2015) Prostatic arterial embolization vs open prostatectomy: a 1\u2011year matched-pair analysis of functional outcomes and morbidities. Urology 86(2):343\u2013348","journal-title":"Urology"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-020-01149-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-020-01149-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-020-01149-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T13:38:41Z","timestamp":1613741921000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-020-01149-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,18]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["1149"],"URL":"https:\/\/doi.org\/10.1007\/s00120-020-01149-1","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,18]]},"assertion":[{"value":"18 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>D.S.\u00a0Sch\u00f6b<\/b>: A.\u00a0Finanzielle Interessen: BMBF F\u00f6rderung im Rahmen des Projektes \u201eViSimon\u201c (F\u00f6rderkennzeichen 16SV7862) \u2013 kein Bezug zum Thema dieses Beitrags. \u2013 Reisekostenerstattung durch COOK Medical f\u00fcr Workshop zur endoskopischen Therapie des Urothelkarzinoms des oberen Urogenitaltrakts, Barcelona, Spanien. \u2013 Ehefrau ist Angestellte der Stryker AG. \u2013 B.\u00a0Nichtfinanzielle Interessen: Facharzt am Universit\u00e4tsklinikum Freiburg | Mitgliedschaften: DGU, EAU, GESRU.<b>A.\u00a0Gross<\/b>: A.\u00a0Finanzielle Interessen: Referentenhonorar oder Kostenerstattung als passiver Teilnehmer: Fa. Cook Medical. \u2013 Bezahlter Berater\/interner Schulungsreferent\/Gehaltsempf\u00e4nger o.\u202f\u00e4.: OP Seminare: Cook Medical. \u2013 B.\u00a0Nichtfinanzielle Interessen: Chefarzt, Klinik f\u00fcr Urologie, Asklepios Klinik Barmbek.<b>D.\u00a0Abt<\/b>: A.\u00a0Finanzielle Interessen: D. Abt gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B.\u00a0Nichtfinanzielle Interessen: Leitender Arzt & Co-Leiter \u201eExperimentelle Urologie\u201c, Klinik f\u00fcr Urologie, Kantonsspital St. Gallen, Schweiz | Mitgliedschaften: Arbeitskreis benignes Prostatasyndrom der Deutschen Gesellschaft f\u00fcr Urologie, Mitglied verschiedener urologischer Fachgesellschaften: SGU, DGU, EAU, AUA, Endourological Society.<b>A.C.\u00a0Reichelt<\/b>: A.\u00a0Finanzielle Interessen: A.C.\u00a0Reichelt gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B.\u00a0Nichtfinanzielle Interessen: angestellte wissenschaftliche Mitarbeiterin, Klinik f\u00fcr Urologie, Universit\u00e4tsklinikum Freiburg.<b>C.\u00a0Gratzke<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Astellas Pharma, Bayer, GSK, MSD and Recordati. \u2013 Referentenhonorar oder Kostenerstattung als passiver Teilnehmer: Amgen, Astellas Pharma, Bayer, GSK, Ipsen, Janssen, Lilly Pharma, Recordati, Pfizer, Rottapharm, STEBA Biotech. \u2013 Bezahlter Berater\/interner Schulungsreferent\/Gehaltsempf\u00e4nger o.\u202f\u00e4.: Astellas Pharma, Bayer, GSK, Janssen, Recordati, Pfizer, STEBA Biotech. \u2013 B.\u00a0Nichtfinanzielle Interessen: Direktor der Urologischen Klinik, Uniklinik Freiburg | Mitgliedschaften in Fachgesellschaften: DGU, EAU, AUA, ASCO.<b>A.\u00a0Miernik<\/b>: A.\u00a0Finanzielle Interessen: Forschungsmittel: Bundesministerium f\u00fcr Bildung und Forschung (BMBF), Deutschland, Europ\u00e4ische Kommission, Luxembourg. \u2013 Reisesponsoring: Deutsche Gesellschaft f\u00fcr Urologie, DE, Europ\u00e4ische Gesellschaft f\u00fcr Urologie, Niederlande, Amerikanische Gesellschaft f\u00fcr Urologie, USA. \u2013 Verlag Walter de Gruyter, Deutschland (Autor) | Richard Wolf GmbH, Deutschland (Referent) | Karl Storz, Tuttlingen, Deutschland (Berater) | Medi-tate, Or Akiva, Israel (Berater) | Lisa laser OHG, Deutschland (Berater) | Optimed GmbH, Deutschland (Berater) | Ludwig Boltzmann-Gesellschaft, \u00d6sterreich. \u2013 B.\u00a0Nichtfinanzielle Interessen: Deutsche Gesellschaft f\u00fcr Urologie | Europ\u00e4ische Gesellschaft f\u00fcr Urologie | Endourological Society.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}